Approach to Evaluating Hypercalcemia in an Outpatient Setting

Initial Assessment

The American Thoracic Society recommends classifying severity of hypercalcemia as mild (>5.0 to <5.5 mEq/L), moderate (5.5 to 6.0 mEq/L), or severe (>6.0 mEq/L or >14.0 mg/dL) 1, 2
Evaluate for symptoms based on severity and acuity of onset, including polyuria, polydipsia, nausea, confusion, vomiting, abdominal pain, myalgia in mild/moderate cases, and mental status changes, bradycardia, hypotension, dehydration, acute renal failure in severe cases 2, 3

The American College of Chest Physicians recommends laboratory evaluation including serum calcium, albumin, intact parathyroid hormone (iPTH), parathyroid hormone-related protein (PTHrP), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, serum phosphorus, magnesium, blood urea nitrogen, and creatinine 2, 3
Urine calcium/creatinine ratio should be assessed to evaluate for hypercalciuria 4, 5

The European Society for Medical Oncology recommends oral hydration as sufficient for mild asymptomatic hypercalcemia, and rehydration with IV crystalloid fluids not containing calcium for moderate to severe hypercalcemia 6, 7
Bisphosphonates, such as pamidronate and zoledronic acid, are recommended for hypercalcemia of malignancy, with zoledronic acid preferred over pamidronate for initial treatment 8
Denosumab is recommended for patients with refractory hypercalcemia, especially those with renal impairment 8

The American Academy of Pediatrics recommends monitoring calcium levels every 4-6 months until 2 years of age, then every 2 years, and treating with low-calcium diet and increased water intake under medical supervision for pediatric hypercalcemia 4, 5
The American Thoracic Society recommends evaluating for nephrocalcinosis with renal ultrasound if hypercalciuria is present, and considering dose reduction or alternative treatments in patients with renal impairment 4, 5

The National Comprehensive Cancer Network recommends monitoring for complications of treatment, including renal toxicity and osteonecrosis of jaw with bisphosphonates, and hypocalcemia post-treatment with denosumab 7, 8

The American Journal of Kidney Diseases recommends calculating corrected calcium using the formula: Corrected calcium (mg/dL) = Total calcium (mg/dL) - 0.8 × [Albumin (g/dL) - 4] [9]
The American Journal of Kidney Diseases suggests that for a patient with total calcium of 10.9 mg/dL and albumin of 5.0 g/dL, the corrected calcium would be: 10.9 - 0.8 × (5.0 - 4.0) = 10.1 mg/dL 9

The Clinical Cancer Research journal notes that Multiple Endocrine Neoplasia syndromes (MEN1, MEN2) and Hyperparathyroid-jaw tumor syndrome should be considered in the differential diagnosis of hypercalcemia 10

The Clinical Cancer Research journal recommends monitoring calcium levels regularly (every 2-3 months) for patients with mild asymptomatic hypercalcemia (corrected calcium <12 mg/dL) 10

The American Journal of Kidney Diseases warns that hyperalbuminemia can mask true calcium status; always calculate corrected calcium or measure ionized calcium 9